Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial
This is the first study showing anxiolytic effect of an α7-nAChR agonist in humans. VQW-765 is a promising candidate to be developed for on-demand treatment of social anxiety disorder.
Authors
- Yukun Wu
- Michael Mohrman
- Yunsheng He (ORCID: https://orcid.org/0000-0002-8026-4414)
- Mihael H. Polymeropoulos (ORCID: https://orcid.org/0000-0001-5065-5353)
- Christos Polymeropoulos (ORCID: https://orcid.org/0000-0002-8920-8013)
- Gunther Birznieks
- Changfu Xiao
- Sunny O Truslow
Institutions
- Vanda Pharmaceuticals (United States) (US)
Publication Details
- Journal
- The British Journal of Psychiatry
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1192/bjp.2025.84
- Citations
- 2
- Primary Topic
- Nicotinic Acetylcholine Receptors Study
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Georgetown University
- Vanda Pharmaceuticals
- NYU Grossman School of Medicine